Clinical Trial Update: SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of SYS6002 with JMT101 and Enlonstobart Injection in participants with head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Enlonstobart Injection
• JMT101
• SYS6002

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING